Core Viewpoint - A class action lawsuit has been filed against Neumora Therapeutics, Inc. for alleged securities fraud and unlawful business practices following disappointing clinical trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit is initiated by investors who believe Neumora and its officers engaged in securities fraud [2]. - Investors have until April 7, 2025, to request appointment as Lead Plaintiff if they purchased Neumora securities during the Class Period [3]. Group 2: Company Performance and Events - Neumora conducted its initial public offering (IPO) on September 15, 2023, selling 14.71 million shares at $17.00 per share [3]. - On January 2, 2025, Neumora announced the KOASTAL-1 study results for Navacaprant, which failed to show statistically significant improvement in key endpoints, leading to a significant stock price drop of $8.63, or 81.42%, closing at $1.97 per share [4].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud affecting investors who purchased its common stock since September 15, 2023 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Neumora Therapeutics, Inc. [2] - The complaint alleges that Neumora made false statements and concealed critical information regarding its Phase Three Program and the Phase Two trials of its flagship therapeutic candidate, Navacaprant [3]. - Specific allegations include the amendment of trial inclusion criteria to show statistically significant improvement in treating Major Depressive Disorder (MDD) and the addition of a prespecified analysis that lacked adequate data [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until April 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. for allegedly making materially false and misleading statements in its Offering Documents related to its initial public offering on September 15, 2023 [1] Group 1: Allegations Against Neumora - The lawsuit claims that Neumora amended its Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2] - It is alleged that Neumora added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2] - The complaint states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which affected the ability to predict results of the KOASTAL-1 study accurately [2] Group 2: Lead Plaintiff Process - Neumora investors can seek to be appointed as a lead plaintiff representative of the class by April 7, 2025, or may choose to remain absent [3] - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3] - The decision to serve as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3] Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages Neumora investors who have suffered losses to contact them for more information [4] - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit related to its IPO, alleging violations of the Securities Act of 1933 due to misleading information regarding its clinical trials and subsequent stock performance [1][3][4]. Company Overview - Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases [2]. - The company acquired its flagship therapeutic candidate, Navacaprant, through the acquisition of BlackThorn Therapeutics, Inc. in September 2020 [2]. IPO Details - Neumora conducted its initial public offering (IPO) on September 15, 2023, selling 14.7 million shares at a price of $17.00 per share [2]. - Following the IPO, the stock price has significantly declined, reaching a closing price of $1.91 per share on February 5, 2025, representing an 88.7% decrease from the IPO price [4]. Allegations in the Lawsuit - The lawsuit claims that the IPO offering documents were materially false and misleading, particularly regarding the Phase Two Trial inclusion criteria and the adequacy of data for predicting results in the KOASTAL-1 study [3]. - It is alleged that Neumora had to amend the original Phase Two Trial criteria to include a patient population with moderate to severe major depressive disorder to justify its Phase Three Program [3]. - The company disclosed on January 2, 2025, that the KOASTAL-1 study failed to show a statistically significant improvement on key endpoints, which contributed to the decline in stock value [4]. Legal Process - Investors who purchased Neumora common stock in connection with the IPO have until April 7, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [5].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements and inadequate data regarding its clinical trials, particularly related to its experimental depression treatment, navacaprant [4][5]. Group 1: Legal Actions and Investigations - Faruqi & Faruqi, LLP is investigating potential claims against Neumora and has set an April 7, 2025 deadline for investors to seek the role of lead plaintiff in the class action [2]. - Investors who suffered losses exceeding $50,000 in Neumora's IPO are encouraged to contact the firm to discuss their legal options [1]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora and its executives violated federal securities laws by making false statements and failing to disclose critical information about the Phase Two and Phase Three clinical trials [4]. - Specific allegations include the amendment of trial inclusion criteria to show statistically significant results and the lack of adequate data in the Phase Two Trials, which affected the predictability of the Phase III study results [4]. Group 3: Impact on Stock Performance - Following the announcement of the failure of navacaprant in the Phase III Koastal-1 trial, Neumora's stock price dropped by 81%, closing at $1.97 per share on January 2, 2025 [5].

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=130538&from=4CLASS PERIOD: T ...

RADNOR, Pa., Feb. 19, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora") (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the "Offering Documents") issued in connection with Neumora's initial public offering held on or aro ...

RADNOR, Pa., Feb. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Documents ...

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading information in its IPO registration statement, which has resulted in significant financial losses for investors [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Chang v. Neumora Therapeutics, Inc., allows purchasers of Neumora's common stock from its IPO on September 15, 2023, to seek lead plaintiff status until April 7, 2025 [1][5]. - The lawsuit alleges that Neumora and its executives misled investors regarding the efficacy of its flagship therapeutic candidate, Navacaprant, particularly in relation to its Phase Two and Phase Three clinical trials [2][3]. Group 2: Financial Impact - Neumora's IPO involved the sale of 14.7 million shares at a price of $17.00 per share [2]. - Following the announcement of the KOASTAL-1 study results on January 2, 2025, which failed to show significant improvement in depression treatment, Neumora's stock price plummeted to $1.91 per share, marking an 88.7% decline from the IPO price [4]. Group 3: Allegations Against Neumora - The lawsuit claims that Neumora altered the Phase Two Trial criteria to include a broader patient population to support its claims of Navacaprant's effectiveness [3]. - It is alleged that the Phase Two Trials lacked sufficient data, particularly regarding patient demographics, which undermined the reliability of the study results [3]. Group 4: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit, highlighting its track record in securing monetary relief for investors in securities fraud cases [6].

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. for allegedly making materially false and misleading statements in its Offering Documents related to its initial public offering [1][2]. Group 1: Allegations Against Neumora - The lawsuit claims that Neumora amended its Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2]. - It is alleged that Neumora added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2]. - The complaint states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which affected the ability to predict results of the KOASTAL-1 study accurately [2]. Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of fraud and corporate misconduct [4]. - The firm encourages Neumora investors who have suffered significant losses to contact them for more information [4].